Keysight Technologies Inc vs GeneDx Holdings Corp — how do they compare? Keysight Technologies Inc trades at $353.74 (market cap $58.74B), while GeneDx Holdings Corp trades at $83.6 (market cap $2.44B). The key difference: Keysight Technologies Inc is far larger — about 24.1× GeneDx Holdings Corp's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| KEYS | WGS | |
|---|---|---|
Market Cap | $58.74B | $2.44B |
Sector | Technology | Technology |
52-Week High | $373.34 | $167.51 |
52-Week Low | $158.51 | $34.51 |
Enterprise Value | $59.08B | $2.48B |
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $335.41, down 1.63% on the day, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a 17.31% net income margin and consistent earnings beats, with Q1 2026 EPS of $2.87 surpassing the $2.32 estimate. Recent developments include new product launches and strategic collaborations, such as the certification of electromagnetic design software for Intel's latest processes (Business Wire, 2026-07-27).
The outlook for KEYS is positive, driven by earnings growth and innovation in test and measurement solutions. Key opportunities include expansion in 5G and cybersecurity markets, though risks involve high valuation multiples and competitive pressures. The consensus price target of $396.56 implies significant upside potential from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →